Skip to main content

Developing Multimodal Therapies for Brain Disorders Proceedings of a Workshop (2017) / Chapter Skim
Currently Skimming:

6 Developing Multimodal Therapies: Practical Considerations Relating to Industry
Pages 47-52

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 47...
... . • Altering practice patterns among physicians will require increased data regarding comparative benefits to existing treatments, education, and new business models (Lisanby, Nye)
Read the entire page →
From page 48...
... Despite the superiority of TMS in treating depression, the market uptake has been much slower than for antidepressants. The reasons for limited market uptake include psychiatric practice patterns, patient burden, high cost and low levels of reimbursement by payers, and limited evidence of the comparative effectiveness of TMS to pharmacotherapy, said Nye.
Read the entire page →
From page 49...
... Alternative providers such as TMS treatment centers, as well as less expensive, mobile devices that require less medical supervision, could also dramatically influence usage and uptake. Sarah Lisanby added that another factor affecting uptake of TMS is increased competition from device manufacturers, and she cited the need for new business models that make financial sense for clinical programs.
Read the entire page →
From page 50...
... , and stumbled on a side effect with potential therapeutic benefit: lower blood pressure due to activation of alpha2 adrenoceptors on presynaptic sympathetic fibers in the lateral horn of the spinal cord. They are now investigating whether this side effect could be turned into a therapeutic effect for hypertensive patients (Komanski et al., 2015)
Read the entire page →
From page 51...
... , the drug manufacturer and the commercial owner of the clinical data North Bristol NHS Trust (Bristol, United Kingdom) , the regulatory sponsor and academic owner of the clinical data; Renishaw plc (Bristol, United Kingdom)
Read the entire page →
From page 52...
... , added another twist to the potential for CED: viral delivery of compounds or biologics, including gene therapy. Several workshop participants note that the GDNF−CED example demonstrates a number of common issues related to the development of multimodal therapies that present challenges to companies working in isolation, or even to small companies with limited resources.
Read the entire page →

Key Terms

  • north bristol
  • pfizer inc
  • chronic pain
  • practice patterns
  • multimodal therapy

  • clinical data
  • treat chronic
  • effect size
  • data north
  • future multimodal

  • bringing multimodal
  • require increased
  • tms therapy
  • effective collaborations
  • spinal cord

  • complex partnerships
  • global infrastructure
  • influence usage
  • dramatically influence
  • pressure due

  • drug interactions
  • biotechnology company
  • bristol national
  • licensed gdnf
  • design changes

  • imposes substantial
  • require additional
  • increased therapeutic
  • pain specialists
  • marked improvement


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.